Rapid Uptake Products (RUPs)
The Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date.
Find your nearest AHSN
The HIN will be supporting the adoption of the following innovations through the RUP Programme during 2021:
• Lipid Management : High Intensity Statins, Ezetimibe and PCSK9 inhibitors
• Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
• Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab
• Tamoxifen for prevention of breast cancer for women at known risk
Applications for Pathway Transformation Funding to help providers overcome practical obstacles to introducing Lipid Management, FeNO testing and Biologics are open from 4 January 2021 until midday, 30 April 2021. Click here to find out more about applying.
Explore our other work in bringing proven innovation to South London stakeholders on our Innovation page or find out more about our current and legacy RUP innovations below.
We're here to help
Interested in adopting a RUP innovation? Please contact email@example.com.Get in touch